PESCI, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 10.657
EU - Europa 4.660
AS - Asia 2.087
SA - Sud America 26
AF - Africa 18
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 17.461
Nazione #
US - Stati Uniti d'America 10.513
IT - Italia 930
DE - Germania 836
CN - Cina 763
SE - Svezia 735
SG - Singapore 691
IE - Irlanda 609
RU - Federazione Russa 407
UA - Ucraina 320
GB - Regno Unito 230
HK - Hong Kong 214
ID - Indonesia 149
FR - Francia 146
CA - Canada 141
FI - Finlandia 126
AT - Austria 123
VN - Vietnam 93
IN - India 77
DK - Danimarca 62
TR - Turchia 38
BE - Belgio 33
CZ - Repubblica Ceca 26
NL - Olanda 26
BR - Brasile 17
ES - Italia 13
JP - Giappone 12
IR - Iran 9
RO - Romania 9
KR - Corea 8
PK - Pakistan 8
CH - Svizzera 7
AU - Australia 6
CL - Cile 6
TH - Thailandia 5
GR - Grecia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
SC - Seychelles 4
BD - Bangladesh 3
EG - Egitto 3
IL - Israele 3
LB - Libano 3
NG - Nigeria 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BG - Bulgaria 2
DZ - Algeria 2
EU - Europa 2
MM - Myanmar 2
MU - Mauritius 2
MX - Messico 2
PH - Filippine 2
A1 - Anonimo 1
AR - Argentina 1
CO - Colombia 1
CR - Costa Rica 1
EC - Ecuador 1
EE - Estonia 1
HU - Ungheria 1
IQ - Iraq 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
NO - Norvegia 1
RS - Serbia 1
TG - Togo 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 17.461
Città #
Ann Arbor 2.538
Fairfield 907
Woodbridge 862
Chandler 851
Frankfurt am Main 615
Dublin 591
Singapore 582
Houston 576
Wilmington 548
Ashburn 501
Dearborn 351
Jacksonville 341
Seattle 337
New York 307
Cambridge 291
Princeton 240
Hong Kong 213
Milan 211
Santa Clara 195
Jakarta 145
Nanjing 143
Vienna 121
Shanghai 120
Altamura 113
Lawrence 105
Beijing 72
San Diego 59
Guangzhou 57
Lachine 56
Boardman 54
Dong Ket 52
Helsinki 49
Nanchang 48
Fremont 42
Toronto 36
Andover 33
Hebei 33
Brussels 32
Jinan 32
Shenyang 30
Lissone 26
Jiaxing 24
Tianjin 24
Brno 21
London 20
Norwalk 19
Falls Church 18
Hangzhou 18
Los Angeles 18
Rome 18
Lappeenranta 17
Ottawa 17
Monza 16
Munich 16
Brescia 15
Mountain View 15
Ningbo 15
Changsha 14
Zhengzhou 13
Pune 12
Edmonton 11
Hefei 11
Florence 10
Beauharnois 9
Kiev 9
Kocaeli 9
Desio 8
Genoa 8
Kunming 8
Paris 8
Phoenix 8
Tappahannock 8
Turin 8
Auburn Hills 7
Chicago 7
Dallas 7
Leawood 7
Washington 7
Ansbach 6
Bari 6
Berlin 6
Groningen 6
Montréal 6
Orange 6
Redmond 6
Sacramento 6
Wuhan 6
Carate Brianza 5
Changchun 5
Nürnberg 5
Padova 5
Sesto San Giovanni 5
Siena 5
Torre Annunziata 5
Upper Marlboro 5
Auckland 4
Bologna 4
Bonndorf 4
Busto Arsizio 4
Fuzhou 4
Totale 13.109
Nome #
Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases 343
Noninvasive ventilation weaning in acute hypercapnic respiratory failure due to COPD exacerbation: A real-life observational study 304
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 292
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 291
Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights 287
Regional differences in bronchial reactivity assessed by respiratory impedance 237
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 231
Response to: Comment on "Noninvasive Ventilation Weaning in Acute Hypercapnic Respiratory Failure due to COPD Exacerbation: A Real-Life Observational Study" 222
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 222
Dyspnea in crackling lungs 218
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 218
Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis 209
Impact of traffic-related air pollution on pulmonary oxidative stress 204
Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia 203
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study 195
Influenza A/H1N1 severe pneumonia: Novel morphocytological findings in bronchoalveolar lavage 193
Renal involvement in Churg-Strauss syndrome 191
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 191
Characterization of bronchiectasis in the elderly 190
162. Cluster analysis to explore clinical subclassification of eosinophilic granulomatosis with polyangiitis (churg–strauss) 190
Progression of obstructive ventilatory disorder in Fabry disease: Only a matter of time? 188
HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome 186
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases 186
Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A single center experience and literature review 186
Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis 185
Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia 183
Bronchoalveolar lavage in idiopathic pulmonary fibrosis: What does it tell us? 180
Persistence with inhaled corticosteroids reduces the risk of exacerbation among adults with asthma: A real-world investigation 178
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 178
A 61-year-old female with chronic cough and purulent sputum 177
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 177
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 177
Prolonged exposure to welding fumes as a novel cause of systemic iron overload 177
Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: Do we need a personalized approach? 176
Clinical phenotypes in adult patients with bronchiectasis 176
Il lavaggio broncoalveolare nelle pneumopatie infiltrative diffuse 174
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 173
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 173
An unusual presentation of pulmonary lymphoma: When diffuse ground glass opacities can mean anything 173
Alpha glucocorticoid receptor expression in different experimental rat models of acute lung injury 171
Management of acute respiratory failure in interstitial lung diseases: Overview and clinical insights 171
Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts 168
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 166
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 165
Metallic elements in exhaled breath condensate of patients with interstitial lung diseases 164
Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity 162
Non-specific interstitial pneumonia and features of connective tissue disease: What are the consequences of a different point of view? 162
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 160
Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy 159
Allergic bronchopulmonary aspergillosis screening in bronchiectasis: Is there always a precise answer to a clear question? 159
Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS? 157
Uterine carcinosarcoma metastatic to the lung as large-cell neuroendocrine carcinoma with synchronous sarcoid granulomatosis 155
Systemic sclerosis and outcome in intensive care unit: Do not close the door, open the right protocol 153
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course 150
Can healthcare utilization data reliably capture cases of chronic respiratory diseases? A cross-sectional investigation in Italy 149
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 147
COPD: maximization of bronchodilation 145
The management of community-acquired pneumonia in the elderly 144
Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy) 143
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study 142
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 139
A case of ARDS associated with influenza A - H1N1 infection treated with extracorporeal respiratory support 136
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 136
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 132
Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis 130
Geriatric multidimensional assessment for elderly patients with acute respiratory diseases 128
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 128
The bronchiectasis severity index. An international derivation and validation study 127
Long-term macrolides in diffuse interstitial lung diseases 127
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 127
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 127
Respiratory system involvement in systemic vasculitides 126
Interstitial lung diseases in a lung cancer screening trial 126
History of lung volume reduction procedures 125
Non-tuberculous Mycobacterial Pulmonary Disease: an Italian National Survey 124
Macrolidi a lungo termine nella broncopneumopatia cronica ostruttiva 122
Optimization of ventilator setting by flow and pressure waveforms analysis during noninvasive ventilation for acute exacerbations of COPD: a multicentric randomized controlled trial 120
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 120
Alveolar Diseases 119
Acute myocardial infarction versus other cardiovascular events in communityacquired pneumonia 116
Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia 116
Respiratory system involvement in ANCA-associated systemic vasculitides 114
Right ventricular reverse remodelling in Idiopathic Pulmonary Arterial Hypertension diagnosed during pregnancy: Is it possible? 113
Bronchoalveolar lavage in intensive care units 112
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 111
The European IPF registry (eurIPFreg): Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis 111
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 110
Outcome and prognostic factors during the course of primary small-vessel vasculitides 107
Cryoglobulinemia 107
Reticular Diseases 105
Cystic Diseases 105
EBUS-TBNA nella patologia mediastino-polmonare: analisi retrospettiva dei primi 3 anni di attività di un singolo centro 104
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 104
Interferon gamma e fibrosi polmonare idiopatica 103
Respiratory System Involvement in Antineutrophil Cytoplasmic-associated Vasculitides: Clinical, pathological, radiological and therapeutic considerations 101
Surgical and endoscopic treatment for COPD: Patients selection, techniques and results 101
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 97
Nodular Diseases 97
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 96
Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis a randomized clinical trial 95
Totale 15.970
Categoria #
all - tutte 65.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.085


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.642 0 0 0 0 0 374 378 220 254 185 152 79
2020/20213.017 112 111 256 348 281 265 291 346 281 312 169 245
2021/20221.968 194 206 232 210 109 161 65 95 75 140 156 325
2022/20233.101 347 865 350 289 186 471 36 179 215 22 82 59
2023/20241.995 52 61 107 97 247 551 367 90 122 33 32 236
2024/20251.857 282 524 250 205 411 185 0 0 0 0 0 0
Totale 18.149